BMO cuts Acadia Pharmaceuticals stock price target on trial miss
BMO Capital reduced its price target for Acadia Pharmaceuticals (ACAD) to $34, citing a trial miss, but maintained an Outperform rating. The stock is down 7.4% over the past week. The firm lowered the success probability for the drug candidate to 35% from 40%. Acadia generated $1.14 billion in revenue over the last twelve months and has a market cap of $3.93 billion.
How this was made
The 30-second read
Why it matters
The trial miss and target cut suggest short‑term downside, but the company's existing product portfolio offers some stability.
Market read
Primary biotech news with immediate price‑target implications; relevant for short‑term traders.
What to watch
Acadia's existing products Nuplazid and Daybue provide cash flow that may cushion the hit.
Background
Acadia Pharmaceuticals reported Phase 2 RADIANT trial results that narrowly missed the primary endpoint, prompting BMO Capital to lower its price target.
Ticker impact
BMO cut Acadia's price target to $34 after the RADIANT trial missed its primary endpoint.
Potential short‑term decline of 5‑10% as investors reassess trial outlook.
Analyst downgrade follows fresh trial data; market typically reacts sharply to biotech trial misses.
Market effects
Biotech sector may see broader risk‑off as trial failures raise concerns on similar pipelines.
U.S. biotech stocks could face modest pressure in early trading.
Limited to investors tracking U.S. pharma/biotech developments.
Counterpoint
If the secondary endpoint holds clinical relevance, the stock could rebound on long‑term potential.
Key entities
- companyAcadia Pharmaceuticals
Biotech firm developing treatments for neuropsychiatric disorders.
- analystBMO Capital
Investment bank that revised ACAD's price target.
